日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NSD2 targeting reverses plasticity and drug resistance in prostate cancer

NSD2靶向治疗可逆转前列腺癌的可塑性和耐药性

Li, Jia J; Vasciaveo, Alessandro; Karagiannis, Dimitris; Sun, Zhen; Gretarsson, Kristjan H; Chen, Xiao; Ouerfelli, Ouathek; Socciarelli, Fabio; Frankenstein, Ziv; Dong, Hanyang; Zou, Min; Yuan, Wei; Yang, Guangli; Aizenman, Gabriel M; Pannellini, Tania; Xu, Xinjing; Beltran, Himisha; Chen, Yu; Gardner, Kevin; Robinson, Brian D; de Bono, Johann; Gozani, Or; Abate-Shen, Cory; Rubin, Mark A; Loda, Massimo; Sawyers, Charles L; Califano, Andrea; Lu, Chao; Shen, Michael M

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells

剪接因子TRA2B增强前列腺癌细胞中雄激素受体变体AR-V7的合成

Brittain, Nicholas; Paschalis, Alec; Nelson, Ryan; Adamson, Beth; Walker, Laura; Duncan, Ruaridh; Smith, Graham R; McGill, Suzanne; Burchmore, Richard Js; Bogdan, Denisa; Jiménez-Vacas, Juan M; Welti, Jonathan; Yuan, Wei; Robson, Craig N; Rescigno, Pasquale; Luzzi, Sara; Sharp, Adam; de Bono, Johann; Gaughan, Luke

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers

雄激素受体剪接变体7的表达水平可以区分AR突变型和非突变型转移性去势抵抗性前列腺癌。

Paschalis, Alec; Figueiredo, Ines; Bogdan, Denisa; Lundberg, Arian; Santos, Rita; Gurel, Bora; Taha, Tarek; Longoria, Ossian; Ferreira, Ana; Bertan, Claudia; Brittain, Nicholas; Nelson, Ryan; Walker, Laura; Neeb, Antje; Welti, Jonathan; Yuan, Wei; Mitsopoulos, Costas; Plymate, Stephen R; Haffner, Michael C; Sowalsky, Adam G; Carreira, Suzanne; Sharp, Adam; Gaughan, Luke; de Bono, Johann

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

综合群体药代动力学、药效学和安全性分析,为ATR抑制剂Tuvusertib的临床开发中的剂量选择提供信息

Mukker, Jatinder Kaur; Diderichsen, Paul Matthias; Hellmann, Farina; Yap, Timothy A; Plummer, Ruth; Tolcher, Anthony W; de Bono, Johann S; Gounaris, Ioannis; Szucs, Zoltan; Zimmermann, Astrid; Kareva, Irina; Bolleddula, Jayaprakasam; Seithel-Keuth, Annick; Locatelli, Giuseppe; Enderlin, Marta; Hicking, Christine; Zutshi, Anup; Gao, Wei; Strotmann, Rainer; Benincosa, Lisa; Venkatakrishnan, Karthik

Molecular landscape of prostate cancers with clival metastases

前列腺癌伴斜坡转移的分子图谱

Likasitwatanakul, Pornlada; Blinka, Steven M; Zarka, Jabra G; Gebrael, Georges; Weg, Emily; Longoria, Ossian; Moore, Joseph A; Sharp, Adam; de Bono, Johann; Sternberg, Cora N; Agarwal, Neeraj; Swami, Umang; Orme, Jacob J; Schweizer, Michael T; Sloan, Lindsey; Hwang, Justin H; Antonarakis, Emmanuel S

Ontology- and LLM-based data harmonization for federated learning in healthcare

基于本体和LLM的数据协调在医疗保健联邦学习中的应用

Kokash, Natallia; Wang, Lei; Gillespie, Thomas H; Belloum, Adam S Z; Grosso, Paola; Quinney, Sara; Li, Lang; de Bono, Bernard

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

研究性ATRi药物Tuvusertib对实体瘤患者QTc间期影响的非临床和临床综合风险评估

Mukker, Jatinder Kaur; Yap, Timothy A; Tolcher, Anthony W; de Bono, Johann S; Plummer, Ruth; Grosser, Gary; van Amsterdam, Christoph; Schieferstein, Hanno; Witjes, Han; Diderichsen, Paul Matthias; Krebs-Brown, Axel; Gao, Wei; Strotmann, Rainer; Szucs, Zoltan; Gounaris, Ioannis; Venkatakrishnan, Karthik

Glucocorticoid-prescribing trends in congenital adrenal hyperplasia, 2017 to 2023

2017年至2023年先天性肾上腺皮质增生症糖皮质激素处方趋势

Roxas, A; Gihawi, A; Makarchuk, M; Bryce, J; Chen, M; Ahmed, S F; Ali, S R; Drake, A; Casipe, M; Groves, L; Idkowiak, J; Krone, R; Flueck, C; Nordenström, A; Reisch, N; Claahsen-van der Grinten, H L; Adriaansen, B P H; Birkebaek, N H; Hannema, S; O Reilly, M W; Cussen, L; Zaric, S P; Neumann, U; Baronio, F; Vieites, A; Alonso, G F; Elsedfy, H; Mazen, I; Thankamony, A; Witczak, J; Rees, D A; Atapattu, N; Seneviratne, S N; Cools, M; El Kaddouri, Hayat; Ferri Perez, Alegria; Guven, A; Poyrazoglu, S; Fu, A; Janus, D; Globa, E; Shenoy, S; de Bruin, C; Korbonits, M; Adam, S; Wasniewska, M; Russo, G; Phan-Hug, F; Bonfig, W; Salerno, M; Tomlinson, J W; Leka-Emiri, S; de Vries, L; Yarhere, I; Guaranga-Filho, G; van Eck, J; Bachega, T A S S; Krone, N; De Bono, M; Davies, J H; Segev-Becker, A; Iotova, V; Lenherr-Taube, N; German, A; Giordano, R; De Sanctis, L; Probst, U; Markosyan, R; Brewer, D S; Costa, E C; Webb, E A

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer

一项针对转移性去势抵抗性前列腺癌患者的JNJ-80038114(一种PSMAxCD3双特异性抗体)的I期、首次人体剂量递增研究

Hudson, Andrew; Jayaram, Anuradha; Garmezy, Benjamin; Zorko, Nicholas A; Zarrabi, Kevin K; Mathews, Ligi; Rupnow, Brent; Li, Mengjie; Ghosh, Debopriya; Urtishak, Karen; Francis, Peter; Wang, Sherry C; Attiyeh, Edward; de Bono, Johann

Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

PSMAfore III期试验的最终总生存期和安全性分析,该试验比较了[(177)Lu]Lu-PSMA-617与更换雄激素受体通路抑制剂治疗既往未接受过紫杉烷类药物治疗的转移性去势抵抗性前列腺癌患者的疗效。

Fizazi, K; Chi, K N; Shore, N D; Herrmann, K; de Bono, J S; Castellano, D; Piulats, J M; Fléchon, A; Wei, X X; Mahammedi, H; Roubaud, G; Fleming, M; Haas, T; Ghebremariam, S; Kreisl, T N; Rajagopalan, S; Sartor, O; Morris, M J